ABL1 and Parkinson disease: Key non-cancer indications for BCR-ABL inhibitors include neurodegenerative diseases, with Alzheimer’s and Parkinson’s diseases frequently being associated, particularly for nilotinib and dasatinib, which have shown preclinical and clinical neuroprotective effects.